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 Abstract 
 
Peroxisome proliferator-activated receptor  (PPAR) is a ligand-dependent transcription 
factor which regulates glucose homeostasis and adipocyte differentiation. Its transcriptional activity is 
regulated by not only ligands but also post-translational modifications (PTMs). In this study, we 
demonstrate a novel E3 ligase of PPAR, TRIM25 directly induces ubiquitination of PPAR followed 
by proteasome-dependent degradation. During the adipocyte differentiation, both mRNA and protein 
expression of TRIM25 significantly decreased and negatively correlated with the expression of 
PPAR. Stable expression of TRIM25 reduces PPAR protein levels, but not mRNA expression, and 
suppressed adipocyte differentiation in 3T3-L1 cells. In contrast, specific knock-down of TRIM25 
increases PPAR protein levels and stimulates adipocyte differentiation. Furthermore, TRIM25 knock-
out mouse embryonic fibroblast (MEFs) shows an increased ability for adipocyte differentiation 
compared with wild-type MEFs. Taken together, these data indicate that TRIM25 is a novel E3 
ubiquitin ligase of PPAR, and depict TRIM25 as a novel target for PPAR-involved metabolic 
diseases. 
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Ⅰ. Background 
1-1. Obesity 
Obesity is defined excessive accumulation of fat in body. Numerically, Body mass index 
(BMI) which is an index of weight for height is commonly used to classify obesity and obesity is a 
BMI greater than or equal to 30 (Fig.1-1). 1 Recently, Obesity has increased as people’s living 
conditions have changed. According to World Health organization (WHO), The fundamental cause of 
obesity is an energy imbalance between calories consumed and calories expended. Obesity is 
preventable because it is not communicable disease by reducing the fat, sugar and salt content food 
and engage in regular physical activity. However, it is hard to maintain lifestyle because people who 
take more energy dense foods and have physical inactivity due to many forms of work have been 
increasing in worldwide.1-5 In addition to increased future risks, obese people experience breathing 
difficulties, increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin 
resistance and psychological effects.5  
1-2. metabolic syndrome 
Metabolic syndrome is associated with abdominal obesity, blood lipid disorders, 
inflammation, insulin resistance or full-blown diabetes, and increased risk of developing 
cardiovascular disease.6 WHO analyzed that Obesity is complex disease and is linked to more deaths 
compared with normal because it is related metabolic syndrome such as diabetes, ischemic heart 
disease and certain cancer (Fig.1-2).7 Many studies suggested that obesity might be causative factors 
in metabolic diseases and cancers. 
1-3. Adipogenesis 
Adipogenesis is one of the process of cell differentiation, which means that preadipocyte 
become adipocyte. Adipocyte differentiation is a complex process involving dramatic changes in cell 
morphology and gene expression. Many transcription factors have been identified as potential 
regulators of this process.8 CCAAT/enhancer binding proteins (C/EBPs) are the master regulators of 
adipogenesis.9 C/EBP- and C/EBP-are expressed at the early stage of adipogenesis  and in turn 
they directly induce expression of peroxisome proliferator-activated receptor  (PPAR) and C/EBP-
, the key transcriptional regulators of adipogenesis which induce their own expression and activate a 
number of target genes (Fig.1-3).11 Although studies continue to increase our understanding of 
adipogenesis, as yet, there is little information about what controls the death or turnover of adipocytes 
in vivo.12 
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1-4. PPAR
Peroxisome proliferator-activated receptor  (PPAR) mainly expressed in adipose tissues and 
it regulates fatty acid storage, glucose metabolism and adipogenesis. PPARγ has been clinically 
related in numerous diseases of including obesity, diabetes, atherosclerosis, and cancer. It also known 
as glitazone receptor because glitazone is ligand of PPARγ such as thiazolidinediones (TZDs) which 
are known class of anti-diabetic drugs. PPARγ agonists have been used in the treatment of 
hyperlipidemia and hyperglycemia,13 and it had reported that PPARγ decreases the inflammatory 
response of many cardiovascular cells, particularly endothelial cells.14 PPARγ increase synthesis and 
release of paraoxonase 1(PON1)  from the liver, reducing atherosclerosis  (Fig 1-4).15  However,  
TZDs have  unwanted side effects, such as weight gain, heart failure.16 Besides of ligands, post-
translational modifications (PTMs), including phosphorylation, SUMOylating, acetylation, and 
ubiquitination of PPAR are considered as one of the major processes regulating the transcriptional 
activity of PPAR.17 Many researchers expected it probably involve changing the way focusing on 
downstream effectors of PPARγ-mediated insulin sensitization, targeting specific post-translational 
modifications of PPARγ and selectively agonizing or antagonizing PPARγ in specific tissues.  
 
1-5. TRIM25 
TRIM25 is known about E3 ubiquitin ligase. Polyubiquitination is the formation of a 
ubiquitin chain on a single lysine residue on the substrate protein.18 These chains are made by linking 
the glycine residue of a ubiquitin molecule to a lysine of ubiquitin bound to a substrate. Lysine 48-
linked polyubiquitin chains target proteins for destruction, by a process known as proteolysis. they 
allow the coordination of cellular signaling such as endocytic trafficking, inflammation, translation, 
and DNA repair.19 It was reported that TRIM25 induces ubiquitination of RIG-1, which is a cellular 
sensor of RNA virus infection and crucial for the cytosolic RIG-I signaling pathway to elicit host 
antiviral innate immunity. TRIM25 interacts with the N-terminal CARDs of RIG-I, this interaction 
effectively delivers the Lys 63-linked ubiquitin moiety to the N-terminal CARDs of RIG-I, resulting 
in a marked increase in RIG-I downstream signaling activity.20 TRIM25 also induces the Lys 48-
linked ubiquitination of Mitochondrial antiviral-signaling protein (MAVS) and degradation by the 
proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like 
receptors.21 14-3-30 is responsible for reduced cell growth, as a factor that interacts with TIM25, it has 
been revealed that TRIM25 is an E3 ubiquitin ligase that targets the proteolysis of 14-3-30 .22 
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Figure 1-1. Age-standardized mean BMI in men by country in 1975 and 2014 
Circulation 2013, 128 (15), 1689-1712. 
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Figure 1-2. Physiology of insulin signaling in metabolic syndrome 
Geneva: World Health Organization 2009, 15. 
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Figure 1-3. Roles of PPARγ and C/EBPα in adipogenesis 
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Figure 1-4. Known effects of PPARγ activation 
Nature Medicine 99, 557–566 (2013). 
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Ⅱ. TRIM25, a novel E3 ligase of PPARγ prevents adipocyte differentiation 
2-1. Introduction 
Adipose tissue has a pivotal role in storing excess energy and is a center for energy 
metabolism.23 Excess body fat is considered one of the major causes of insulin resistance, 
dyslipidemia, type 2 diabetes, certain types of cancer, and cardiovascular disease.24 In obesity, 
adipocytes exhibit the alteration of the status of energy homeostasis not only to store the energy but 
also to generate and secrete hormones and cytokines called adipokines.25 For instance, the expression 
of insulin-resistance-inducing adipokines including TNF-α, IL-1, or resistin were increased in adipose 
tissue from obese individuals, but the production of the insulin-sensitizing hormone, adiponectin or 
adipsin was decreased.26 Furthermore, the defects in adipocyte differentiation or functions increased 
the probability of metabolic disorders. Thus, understanding of detail molecular mechanism in adipose 
tissue biology, especially adipocyte differentiation may provide the insight for treating obesity and 
metabolic syndrome. 
Adipocyte differentiation is tightly controlled by a series of transcriptional factors. A number 
of studies have demonstrated that peroxisome proliferator-activated receptor  (PPAR) and 
CCAAT/enhancer binding proteins (C/EBPs) are the master regulators of adipogenesis.9 The first 
stage of adipogenesis consists of the induction of C/EBP- and C/EBP- and in turn they directly 
induce expression of PPAR and C/EBP-, the key transcriptional regulators of adipogenesis.11 The 
importance of C/EBP- and C/EBP- during adipogenesis is demonstrated by loss-of-function and 
gain-of function genetic studies in mice.27 Mice lacking either C/EBP- or C/EBP- exhibit a reduced 
mass of white adipose tissue.28 In addition, it has been well studied that PPAR and C/EBP- induce 
their own expression and activate a number of target genes such as fatty acid-binding protein (aP2), 
fatty acid synthase (Fasn), CD36, and lipoprotein lipase (LPL).29 C/EBP--null embryonic fibroblast 
cells fail to undergo adipogenesis, but this defect can be restored by overexpression of PPAR.30 
Conversely, forced expression of C/EBP- in PPAR-null embryonic fibroblast cells does not allow 
the cells to differentiate.31 These experiments demonstrate that PPAR is the key transcriptional 
regulator of adipogenesis, and it is both sufficient and necessary for fat cell differentiation.  
It has been well known that the transcriptional activity of PPAR is up-regulated by its 
ligands such as thiazolidinediones (TZDs).32 PPARγ specifically makes a heterodimer with retinoid X 
receptor (RXR) to DNA repeats of the sequence AGGTCA (DR1 elements), and PPARγ/RXR 
heterodimer can regulate variety of target genes in different cells.33 In the resting state (without 
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PPAR ligands), PPARγ preferentially binds to nuclear receptor corepressor 1 (NCOR1) and silencing 
mediator for retinoid and thyroid receptor (SMRT/NCOR2).34 These complexes recruit chromatin-
modifying enzymes such as histone deacetylases to repress transcription.35 However, when the ligands 
activate PPAR, corepressors are dissociated with PPARγ and coactivators such as steroid receptor 
coactivator (SRCs), PPAR coactivator 1s (PGC1s), histone acyltransferases (HATs), and the 
Mediator complex are recruited and interact with PPAR and promote gene transcription.36 Besides of 
ligands, post-translational modifications (PTMs), including phosphorylation, SUMOylating, 
acetylation, and ubiquitination of PPAR are considered as one of the major processes regulating the 
transcriptional activity of PPAR.17 Phosphorylation at Ser112 of PPAR is modified by mitogen-
activated protein kinase (MAPK) and suppresses PPAR transcriptional activity and adipocyte 
differentiation.37 In contrast to Ser112, PPAR phosphorylation at Ser273 by cyclin-dependent kinase 
(CDK5)/ERK did not change its transcriptional activity, but its phosphorylation has important 
implications for the treatment of type 2 diabetes.38 SUMOylating at Lys107 of PPAR blocks 
transcriptional activity and Lys395 of PPAR represses inflammatory genes expression by blocking 
NF-B activation.39 PPAR is also ubiquitinated and degraded in a proteasome-dependent manner.40 
These studies have shown that post-translational modifications of PPAR are important factor for 
physiological role of PPAR. Thus, the characterization of the novel PTMs of PPAR will provide 
important insights for understanding the physiological functions of PPAR in both adipogenesis. 
Tripartite motif (TRIM) proteins are defined as E3 ubiquitin ligases as they contain a ring-
finger domain.41 So far, there are more than 77 known TRIM proteins in human.42 They are involved 
in a broad range of biological processes and the dysfunction of TRIM proteins results in variety of 
pathophysiological conditions.43 It has been known that TRIM25 (also known as EFP) is one of the 
downstream targets of estrogen receptor . The expression of TRIM25 is upregulated in response to 
estrogen, and it is thought to mediate estrogen actions in breast cancer as a primary response gene.44 
In addition, TRIM25 induces the ubiquitination of retinoic acid inducible gene 1 (RIG-I) and regulates 
host anti-viral innate immunity.45  
In this study, we report the novel roles of TRIM25 in regulating metabolic pathways by 
mediating PPAR ubiquitination and proteasome-dependent degradation. The physiological function 
of TRIM25 on PPAR protein stability is further confirmed in both 3T3-L1 adipocytes and TRIM25 
knock-out MEFs, suggesting that TRIM25 directly regulates PPAR protein stability, which controls 
adipocyte differentiation. Together, these results demonstrate that TRIM25 may be a potential 
therapeutic target in PPAR-mediated metabolic diseases such as obesity and type 2 diabetes. 
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2-2. Materials and Methods 
Cell culture  
3T3-L1 and HEK-293 cells were obtained from ATCC (VA, USA) and cultured in in 
Dulbecco's modified Eagle's medium (DMEM) containing Bovine Serum (Gibco BRL, NY, USA) and 
antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) at 37 °C under a humidified 5% CO2 
atmosphere. PPARγ-deficient MEFs have been described previously.11 Adipocyte differentiation was 
induced by treating cells with DMEM medium containing 10% fetal bovine serum (FBS; Gemini Bio-
Products, Inc.), 0.5 mM isobutylmethylxanthine, 1 μM dexamethasone and 850 nM insulin. Two days 
after the induction, cells were switched to the maintenance DMEM medium containing 10% FBS and 
850 nM insulin. Lipid accumulation in the cells was detected by Oil Red O (Sigma) staining. Mouse 
embryonic fibroblast cells (MEFs) and TRIM25 deletion MEFs were kindly provided by Dr. Kyung-
soo Inn.46 
Plasmid constructs and shRNAs  
The mammalian expression vector for Flag-epitope tagged wild-type PPARγ, Which was 
described previously.11 Murine TRIM25 and its deletion mutants were kindly provided by Dr. V. 
Narry Kim.47 The sequence used for lentiviral shRNA expression vector (pLKO.1; GE Healthcare, 
Dharmacon) targeting TRIM25 is 5' - AAACCCAGGGCTGCCTTGGAAAAG - 3'. For lentivirus 
production, 3T3-L1 cells (ATCC, VA, USA) were transfected with 10 μg lentiviral vectors. Following 
infection of the cells with the lentivirus, cells were selected by incubation with 1 μg/ml puromycin.  
Binding assay and immunoprecipitation 
Immobilized GST-fused proteins (PPARγ-AB, DBD/H, LBD, WT, TRIM25-Truncated 
mutant) with glutathione–agarose was incubated with PPARγ or TRIM25-expressing cell lysates for 2 
h at 4 °C. Protein complexes were pulled-down by centrifugation and washed four times with binding 
buffer. Precipitates were detected by immunoblotting using anti-PPARγ or TRIM25 antibodies. For 
analyzing interaction between PPARγ and TRIM25, HEK-293 cells expressing PPARγ, TRIM25 or 
their mutants were lysed with binding buffer and total cell lysates were incubated with FLAG M2 
agarose (Sigma, MO, USA) at 4 °C. Immunoprecipitants or total cell lysates were analyzed with 
specific antibodies as indicated. 
Reporter gene assay 
HEK-293 cells were transfected with pDR-1 luciferase reporter plasmid, PPARγ, RXRα and 
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pRL-Renillia using Lipofectamine 2000 (Invitrogen, CA, USA). Following an overnight transfection, 
the cells were treated with rosiglitazone for 24 h. The cells were harvested, and reporter gene assays 
were carried out using the Dual-Luciferase kit (Promega, WI, USA). Luciferase activity was 
normalized to Renillia activity. 
Gene expression analysis 
Total RNA was isolated from cells or tissues using TRIzol reagent (Invitrogen, CA, USA). 
RNA was reverse-transcribed using an ABI Reverse Transcription Kit. Quantitative PCR reactions 
were performed with SYBR green fluorescent dye on an ABI9300 PCR machine. Relative mRNA 
expression was determined by the ΔΔ-Ct method normalized to 60S acidic ribosomal protein P0 
(RPLP0) levels. 
Identification of the PPARγ binding complexes 
PPARγ or an empty vector were grown to confluence and were induced differentiation as 
described above. At day 6 of differentiation, cells were homogenized in a hypotonic solution (10 mM 
HEPES at pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, protein inhibitors) and spun at 1000 g 
for 15 min to pellet the nuclei. The nucleus fractions were resuspended with a hypertonic solution (20 
mM HEPES at pH 7.9, 400 mM NaCl, 1.5 mMMgCl2, 0.5 mM DTT, 0.2 mM EDTA, 20% glycerol, 
protein inhibitors) for 30 min to extract nuclear proteins. Samples were spun at16, 000 g for 30 min 
and dialyzed against a binding buffer containing 20 mM HEPES (pH 7.9), 150 mM KCl, 0.2 mM 
EDTA, 20% glycerol, 0.5 mM DTT, and 0.1 mM PMSF. The nuclear extracts were incubated 
overnight with FlagM2 agarose (Sigma, MO, USA), washed in a binding buffer (250 mM KCl), and 
then eluted by incubating with 3X Flag peptide (0.2 mg/ml). The eluted materials were separated in a 
4–12% acrylamide gradient gel, and visualized by silver staining. Gel-resolved proteins were excised, 
digested with trypsin, and individually analyzed in an Orbitrap ELITE mass spectrometer (Thermo 
Fisher Scientific, Bremen, Germany). We separated peptides in a C18 reverse phase HPLC column 
(150 mm × 75 μm i.d.) using an acetonitrile/0.1% formic acid gradient of 66 min at a flowrate of 300 
nl/min. For MS/MS analysis the precursor ion scan MS spectra (from m/z 400 to 2000) were acquired 
in the Orbitrap with resolution R = 60,000 at m/z = 400 with an internal lock mass. The 20 most 
intense ions were isolated and fragmented in the linear ion trap by collisionally induced dissociation 
(CID). All MS/MS spectra were searched against the Uniprot protein sequence database by 
SequestHT.  
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In vitro ubiquitination assay 
FLAG-TRIM25 was transiently expressed in HEK-293 cells, purified by 
immunoprecipitation using anti-FLAG M2 affinity gel (Sigma-Aldrich, A2220), and eluted by adding 
FLAG peptide (Sigma-Aldrich, F3290) according to the manufacturer’s instructions. Bacterially 
expressed recombinant GST-PPAR2 was incubated with 200 ng E1 (UBE1, E-305, Boston Biochem, 
Cambridge, MA, USA), 500 ng E2 (UbcH5c, Boston Biochem, E2-627), 10 g Ubiquitin (Sigma-
Aldrich, U6235), 2mM ATP (Cell signaling, 9804) in the absence and presence of FLAG-TRIM25 
wild type or C.S. mutant in 60 l of reaction buffer (40mM Tris-HCl, pH 7.6, 50mM NaCl, and 1mM 
DTT) for 1 h at 37° C. After incubation, reactions were pulled-down by centrifugation and washed 
four times with binding buffer, followed by western blotting using a-Ub-HRP or a-PPARγ mouse 
antibodies. Reactions were directly subjected to western blotting using a-TRIM25 antibodies to see 
TRIM25 self-ubiquitination as a control. 
Animals 
All animal experiments were performed according to procedures approved by Ulsan National 
Institute of Science and Technology's Institutional Animal Care and Use Committee. Five-week-old 
male C57BL/6 J mice (DBL, Korea) were fed a high-fat diet (60% kcal fat, D12492, Research Diets 
Inc., NJ, USA) for 10 weeks. 
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2-3. Results 
TRIM25 directly interacts with PPAR 
To identify potential PTM modulators of PPAR, we performed proteomic analyses of 
binding complexes formed with PPAR. As shown in Fig. 1A, Among multiple PPAR-associated 
proteins, TRIM25 was of particular interest because it functions as an ubiquitin E3 ligase and as an 
ISG15 E3 ligase.48 It has been also reported that TRIM25 involves in innate immune defense against 
viruses by mediating ubiquitination of DDX58. It mediates Lys-63-linked polyubiquitination of the 
DDX58 N-terminal CARD-like region which is crucial for triggering the cytosolic signal transduction 
that leads to the production of interferons in response to viral infection.20 These data led us to 
investigate whether TRIM25 has physiological roles in regulating both PTM and transcriptional 
activity of PPAR. To confirm the interaction between TRIM25 and PPAR, PPAR were 
immunoprecipitated from cultured adipocytes and detected TRIM25 by immunoblotting. As shown in 
Fig. 1B, PPAR interacts with TRIM25. We further investigated the interaction between TRIM25 and 
PPAR in vitro, using recombinant PPAR fragments, including the A/B region which is 
transcriptional regulatory region (A/B), DNA Binding Domain region/Hinge region (DBD/H) and 
Ligand Binding Domain (LBD). As shown in Fig. 1C, TRIM25 directly interacted with the DBD/H 
domain of PPAR. To further determine the specific region required for TRIM25 binding to PPAR 
recombinant glutathione S-transferase (GST)-fused dissected smaller region of TRIM25 fragments 
were generated. Coimmunoprecipitation showed that amino acids 350-400 region of TRIM25 
(TRIM25350-400) is necessary for its interaction with PPAR(Fig. 1D).  
 
The E3 ligase activity of TRIM25 is required to decrease PPAR protein stability 
It has been reported that TRIM25 is known as an E3 ligase, we next examined whether 
TRIM25 regulates protein stability of PPAR. To further elucidate the role of TRIM25 in PPAR 
stability as an E3 ligase, we generated E3 ligase-defective TRIM25 mutant by changing cysteine 50 
residue to serine (C50S) within TRIM25 (TRIM25CS) which is crucial for E3 ligase.32 When 
TRIM25CS mutant was overexpressed with PPAR, it still interacted with PPAR but did not induce 
PPAR degradation, (Fig. 2A). Furthermore, with an increase of TRIM25WT expression does 
dependently decreased PPARγ protein level, but TRIM25CS mutant did not affect (Fig. 2B). These 
results indicated that E3 ligase activities of TRIM25 are involved in PPARγ degradation. Moreover, 
we also examined which region is crucial to TRIM25-mediated PPAR degradation. As shown in Fig 
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1D, full length of TRIM25 (TRIM251-630) and TRIM251-449 fragment containing PPAR binding region 
as well as E3 ligase activity produced PPAR degradation, whereas other fragments including 
TRIM251-185, TRIM25400-630, TRIM25350-630, and TRIM2581-630 without PPAR binding region or E3 
ligase catalytic activity failed to induce PPAR degradation (Fig. 2C).These results indicate that 
TRIM25 mediated PPAR degradation is required for E3 ligase activity of TRIM25 as well as 
interaction between TRIM25 and PPARγ. Interestingly, forced expression of TRIM25 significantly 
reduced the protein level of PPAR, which was recovered and interaction between PPAR and 
TRIM25 was also increased by treatment with MG132, a specific proteasome inhibitor (Fig. 2D). 
Additionally, treatment with MG132 suppressed TRIM25-mediated degradation of PPARγ (Fig. 2E). 
Next, we analyzed the kinetics of the protein levels of PPARγ regulated by TRIM25 using 
cyclohexamide (CHX), an inhibitor of protein translation. TRIM25WT was shown to reduce the half-
life of PPARγ compared to TRIM25CS mutant in 3T3-L1 adipocytes (Fig. 2F), suggesting that 
TRIM25 decreases the half-life of PPARγ expression via proteasomal degradation. 
 
TRIM25 mediates ubiquitination of PPARas an E3 ligase 
We performed ubiquitination analysis to further test whether TRIM25 functions as a specific 
E3 ligase of PPARγ. Retrovirus expressing TRIM25WT or TRIM25CS mutant was transduced into fully 
differentiated adipocytes, then we immunoprecipitated endogenous PPAR cultured adipocytes and 
detected ubiquitination of endogenous PPARγ by western blotting (Fig. 3A). Although the protein 
levels of PPARγ was decreased by TRIM25WT, TRIM25WT resulted in increased PPARγ ubiquitination 
under pretreatment with MG132. However, TRIM25CS was not able to induce PPARγ ubiquitination. 
Consistent with these results, transiently expressed TRIM25WT more enhanced PPARγ ubiquitination 
compared to TRIM25CS mutant in HEK-293 cells (Fig. 3B). To further confirm the effect of TRIM25 
on PPAR, we next performed in vitro ubiquitination assay using purified TRIM25 and PPARγ. As 
expected, TRIM25 also induce ubiquitination of recombinant PPARγ (Fig. 3C), whileTRIM25CS did 
not (Fig. 3D). These results suggest that PPAR is a substrate of TRIM25.  
 
Expression of TRIM25 is decreased during adipogenesis 
In present study, our results demonstrated that TRIM25 regulated PPAR protein stability. 
Thus, we next further investigate the physiological role of TRIM25 in adipocyte differentiation. At 
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first, we examined the physiological relevance of TRIM25 and PPAR during adipocyte 
differentiation. Western blot analysis and real-time PCR analysis revealed that TRIM25 was expressed 
in pre-adipocytes and its expression was significantly decreased during adipogenesis (Fig. 4A and B). 
Contrast with TRIM25 expression, PPARγ and adipogenic marker genes, including aP2 and 
adiponectin were significantly increased, indicating that TRIM25 expression is negatively correlated 
with that of PPARγ. Furthermore, we also measured TRIM25 expression in adipose tissue from diet-
induced obesity model mouse (DIO mouse) and genetically induced obesity model mouse (ob/ob 
mouse. Fig. 4C and D showed that TRIM25 expression significantly down regulated, while PPARγ 
expression was dramatically up-regulated in adipose tissue from both DIO mouse and ob/ob mouse 
compared with control mouse.  Together, these results suggest that the expression of TRIM25 
inversely correlated with that of PPARγ in vitro and in vivo.   
 
TRIM25 suppresses adipocyte differentiation 
PPARγ is both necessary and sufficient for adipogenesis, and alterations in PPARγ activity 
affect adipogenesis.30 Consistent with TRIM25-mediated regulation of PPARγ stability, differentiation 
of 3T3-L1 cells was suppressed in expressed TRIM25WT, mature adipocytes was evaluated by 
determination of triglyceride (TG) accumulation using Oil Red O staining (Fig. 5A). Furthermore, the 
protein and mRNA expression of adipocyte-selective genes, including aP2, CCAAT/enhancer-binding 
protein a (C/EBP a), adiponectin, adipsin, lipoprotein lipase (LPL), and glucose transporter-4 
(GLUT4), were also reduced (Fig. 5B and 5C). However, TRIM25CS mutant did not alter expression 
of adipogenic markers. In addition, specific knockdown of TRIM25 enhanced adipocyte 
differentiation (Fig. 6A) and the expression of adipocyte-specific proteins and genes compared with 
specific knockdown of TRIM25 using a lentivirus expressing a short hairpin (sh) RNA targeting 
TRIM25 (Fig. 6B and 6C). To investigate the effect of the TRIM25 on PPARγ transcriptional activity, 
we performed dual luciferase system in HEK-293 cells expressing a PPRE-containing luciferase 
construct. As shown in Fig. 5D, overexpression of TRIM25WT suppressed PPARγ transcriptional 
activity of PPARγ, but TRIM25CS did not affect. Consistent with this result, specific knockdown of 
TRIM25 promoted PPARγ transcriptional activity (Fig. 6D). To further confirm the effect of TRIM25 
in adipogenesis, we used wild type and TRIM25 knock-out (KO) mouse embryonic fibroblasts 
(MEFs). Compared to WT MEFs, KO MEFs exhibited dramatically enhanced lipid accumulation 
(Fig. 7A). Furthermore, the expression of adipogenic markers significantly increased in KO MEFs 
compared to WT MEFs (Fig. 7B and 7C). Taken together, these results suggest that TRIM25 plays a 
key role in the regulation of PPARγ-dependent adipogenic processes. 
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2-4. Discussions 
 Adipose tissue is the center of regulating systemic metabolism in rodent and human. 
Dysregulation of adipocyte differentiation and/or physiological functions result in metabolic disorders 
such as type 2 diabetes.25 As PPARγ functions as a master regulator of fat cell differentiation and 
glucose/lipid metabolism, understanding mechanisms of PPARγ regulation is crucial for combating 
metabolic disorders. PPARγ activity is regulated by its ligand as well as by modulating its protein 
level. PPARγ (+/−) heterozygous mice are protected from high-fat diet-induced weight gain and 
insulin resistance.49-51 These findings suggest that abundance of PPARγ proteins itself in adipose 
tissue can also ameliorate obesity and insulin resistance.   
The ubiquitin-proteasome pathway involves an enzymatic cascade, through which multiple 
ubiquitin molecules are covalently attached to a substrate. The polyubiquitinated substrate is then 
recognized by the 26S proteasome and degraded. Ubiquitin is shuttled to the substrate via a series of 
enzymatic transfers originating with the ubiquitin activating enzyme (E1) and ending with 
modification of the substrate by the ubiquitin polypeptides, catalyzed by one or more ubiquitin ligases 
(E3).52 The E3 ubiquitin ligases determine the specificity of substrate selection by the ubiquitin-
proteasome system.20, 48 PPARγ protein stability and activity are also controlled by the ubiquitin 
proteasome system. Thus, identification of the ligase or ligases required for ubiquitination of PPARγ 
in adipocyte is essential for understanding the physiological significance of PPARγ ubiquitin 
modification in adipocytes. In this study, we showed TRIM25 is direct E3 ligase to target PPAR. 
TRIM25 reduced PPAR protein levels through direct interaction through DBD/H domain within 
PPAR and TRIM25350-400 region. In addition to direct interaction, E3 ligase catalytic activity is also 
essential for TRIM25-mediated regulation of PPARstability and adipocyte differentiation. Thus, our 
results demonstrate that TRIM25 is a novel regulator of PPAR mediating ubiquitination and 
degradation of PPAR. Interestingly, poly-ubiquitination process of PPARγ is not always lead to 
proteasomal degradation and down regulation of PPAR activity.33-35 Of course, in our study, TRIM25 
induced ubiquitination and degradation of PPARγ and suppressed adipocyte differentiation. 
Furthermore, MKRN1 mediated PPARγ ubiquitination and degradation to target for ubiquitination at 
lysine 184 and 185 residues in PPARγ.53 FBXO9  directly interacted with PPARγ through the 
activation function-1 domain and ligand-binding domain, which also decreased the protein stability of 
PPARγ through induction of ubiquitination.54 In contrast, NEDD4 interacts with the hinge and LBD of 
PPARγ and increases ubiquitination but it also increases PPARγ stability to inhibit proteasomal 
degradation.55 Siah2 causes PPARγ degradation but it also up-regulates ligand-dependent activation of 
PPARγ.56 tripartite motif protein 23 (TRIM23) regulates PPARγ ubiquitination to stabilize it.57 These 
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findings demonstrate important roles for E3 ligases in PPARγ posttranslational regulation, but it is 
not unclear to make different results in PPAR stability. Therefore, further studies are required to 
understand how ubiquitination affect PPAR protein stability and activity. We will examine how 
TRIM25 plays a central role on PPARγ in a ligand-dependent manner for future studies. 
In this study, we found TRIM25 as binding protein of PPARγ in adipocyte and their 
expression showed inverse correlation in adipose tissue and adipocyte (Fig 4). Interestingly, TRIM25 
and PPARγ are not only expressed in adipocytes but also in other tissue. And, interestingly, they also 
have inversed function in cancer. Many studies have been reported PPARγ as a tumor suppressor 
because it has a role of inflammation and glucose metabolism in cancer.58-61 Overexpression of PPARγ 
suppressed survival to inhibit cell proliferation and tumor growth.62-63 In contrast, silence of PPARγ in 
cancer has reverse effects to activate cancer survival pathway. 64-67 TRIM25 also has been studying 
related several cancers. Especially, TRIM25 is over-expressed in breast, ovarian and lung cancer, 
while PPARγ is down regulated in these cancer compare with non-cancer line.68-69 These results shows 
that the possibility that TRIM25 also related in estrogen target cancer by regulating PPAR stability as 
tumor suppressor. After study that targets TRIM25 may advance in the development of novel therapy 
for selective PPARγ stability and activity as modulators. 
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Figures 
 
 
Figure 1. TRIM25 directly interacts with PPARγ 
(A) The silver staining of PPARγ and its associated proteins. Flag-tagged PPARγ and empty vector 
were expressed PPARγ-deficient mouse embryonic fibroblasts (MEFs). At day 6 of differentiation, 
cells were homogenized, and the nuclear extracts were used for immunoprecipitation. PPARγ 
complexes were visualized by silver staining and analyzed by LC MS/MS. 
(B) Endogenous PPARγ was immunoprecipitated with anti- PPARγ antibody. The precipitates were 
analyzed with anti-TRIM25 antibody. 
(C) GST-fused A/B, LBD, DBD/H, and full-length PPARγ proteins were incubated with TRIM25-
expressing cell lysates. The complexes of GST-fragments were isolated using GSH Sepharose, and 
analyzed by western blotting with anti-TRIM25 antibody. 
(D) GST-fused TRIM25 fragments (TRIM251-630, TRIM251-185, TRIM251-449, TRIM2581-630, 
TRIM25350-630, and TRIM25450-630) were incubated with recombinant PPARγ protein. The TRIM25 
complexes were isolated using GSH Sepharose, and analyzed by western blotting using anti-PPARγ 
and TRIM25 antibodies.  
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Figure 2. E3 ligase activity of TRIM25 is necessary for its ability for regulating PPARγ stability 
(A) Interaction between exogenous TRIM25WT, TRIM25CS and PPARγ. HEK-293 cells were 
transfected with the plasmids expressing FLAG-PPARγ and HA- TRIM25WT, TRIM25CS plasmids. 
The transfected cells were then harvested and WCE were immunoprecipitated using FLAG 
antibodies, followed by western blotting using FLAG and HA antibodies. 
(B) GST-fused TRIM25 fragments (TRIM251-630, TRIM251-185, TRIM251-449, TRIM2581-630, 
TRIM25350-630, and TRIM25450-630) were incubated with recombinant PPARγ protein. The TRIM25 
complexes were isolated using GSH Sepharose, and analyzed by western blotting using anti-PPARγ 
and TRIM25 antibodies.  
(C) HEK-293 cells, transfected with the expressing PPARγ (2 g), TRIM25WT, TRIM25CS (0.5 g) 
and increasing concentrations of HA- TRIM25WT, TRIM25CS (0.5 and 1 g), were treated. The 
proteins were detected by western blotting. 
(D) Interaction between exogenous TRIM25 and PPARγ. HEK-293 cells were transfected with the 
plasmids expressing FLAG-PPARγ and HA-TRIM25 plasmids with or without 10 μM MG132 for 
6 h. The transfected cells were then harvested and WCE were immunoprecipitated using FLAG 
antibodies, followed by western blotting using FLAG and HA antibodies. 
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(E) Effects of MG132 on TRIM25-mediated PPARγ degradation. HEK-293 cells, transfected with the 
expressing PPARγ (2 g), TRIM25 (0.5 g) and increasing concentrations of HA-TRIM25 (0.5 and 1 
g), were treated with 10 M MG132 for 6 h. The proteins were detected by western blotting.  
(F) Half-life of PPARγ in the presence of TRIM25. HEK-293 cells were transfected with plasmids 
expressing indicated proteins followed by treatment with CHX. WCE were perceived by western 
blotting. 
All represented error bars are S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control. 
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Figure 3. E3 ligase of TRIM25 is required for PPARγ ubiquitination 
(A) PPARγ ubiquitination by active TRIM25 E3 ligase. 3T3-L1 cells, transfected FLAG-PPARγ and 
HA- TRIM25WT, TRIM25CS plasmids with 10 μM MG132 for 6 h. The transfected cells were then 
harvested and WCE were immunoprecipitated using FLAG antibodies, followed by western blotting 
using Ubiquitin and FLAG, HA antibodies. 
(B) HEK-293 cells, transfected HA- TRIM25WT, TRIM25CS plasmids with 10 μM MG132 for 6 h. 
The transfected cells were then harvested and WCE were immunoprecipitated using PPARγ 
antibodies, followed by western blotting using Ubiquitin and FLAG, HA antibodies. 
(C-D) Ubiquitination of PPARγ by TRIM25 in vitro. Purified recombinant GST- PPARγ was 
incubated with E1, E2, ubiquitin (Ub) and ATP in the absence and presence of HA- TRIM25WT or/and 
TRIM25CS as indicated followed. Reactions were boiled in 1% SDS to disrupt protein interaction, 
followed by immunoprecipitation using PPARγ antibodies. Ubiquitination of PPARγ was analyzed by 
western blotting using Ub or PPARγ antibodies. For input, ubiquitin reactions were directly subjected 
to western blotting using TRIM25 antibodies. 
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Figure 4. Reverse correlation between TRIM25 and PPARγ expression 
(A-B) 3T3-L1 pre-adipocytes were induced to undergo adipogenesis and the cells were harvested each 
day as indicated. (A), WCE were harvested and followed by western blotting as indicated antibodies. 
(B), RNA isolated and subjected to real-time PCR to determine the level of TRIM25 and indicated 
mRNA expressions. 
(C-D) TRIM25 and PPARγ expressions in WAT. Quantification of PPARγ compared to TRIM25 was 
performed to use WAT of High fat diet mouse and Ob/Ob mouse. (n=4). (C), Lysates of tissues were 
followed by western blotting using indicated antibodies. (D), RNA isolated and subjected to real-time 
PCR to determine the level of TRIM25 and PPARγ mRNA. 
All represented error bars are S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control. 
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Figure 5. TRIM25 suppresses adipocyte differentiation in 3T3-L1 
(A-C) Empty vector, TRIM25WT and TRIM25CS expressing 3T3-L1 cells were induced adipocyte 
differentiation for 6 days. (A), Cells were stained with Oil Red O.  (B), These cells were then 
harvested and WCE were followed by western blotting as indicated above and (C), analyzed mRNA 
expression of adipogenic genes. 
(D) Transcriptional activity of a PPAR-derived reporter gene in HEK-293 cells following 
overexpression TRIM25WT and TRIM25CS. The cells were incubated with or without rosiglitazone 
(10μM) for 24 hr. harvested, and quantified firefly luciferase. WCE were perceived by western 
blotting and their levels measured. 
All represented error bars are S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control. 
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Figure 6. Knockdown of TRIM25 increases adipocyte differentiation in 3T3-L1 
(A-C) Scr shRNA or shRNA against TRIM25 was infected into 3T3-L1 cells, and cells were induced 
adipocyte differentiation. (A), Cells were stained with Oil Red O.  (B), These cells were then 
harvested and WCE were followed by western blotting as indicated above and (C), analyzed mRNA 
expression of adipogenic genes. 
(D) Transcriptional activity of a PPAR-derived reporter gene in HEK-293 cells following Scr shRNA 
or shRNA against TRIM25 was infected. The cells were incubated with or without rosiglitazone 
(10μM) for 24 hr. harvested, and quantified firefly luciferase.  
All represented error bars are S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control. 
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Figure 7. TRIM25 regulates adipocyte differentiation in MEFs 
(A-C) Mouse embryonic fibroblast cells (MEFs) and TRIM25 deletion MEFs were induced adipocyte 
differentiation. (A), Cells were stained with Oil Red O.  (B), These cells were then harvested and 
WCE were followed by western blotting as indicated above and (C), analyzed mRNA expression of 
adipogenic genes. 
All represented error bars are S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control. 
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